The Neurofibroma drugs in development market research report provides comprehensive information on the therapeutics under development for Neurofibroma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neurofibroma. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Neurofibroma - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neurofibroma and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Neurofibroma by seven companies/universities/institutes. The top development phase for Neurofibroma is phase ii with seven drugs in that stage. The Neurofibroma pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Neurofibroma pipeline products market are: Novartis, Exelixis and Ashvattha Therapeutics.

The key targets in the Neurofibroma pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2), Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), and Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1).

The key mechanisms of action in the Neurofibroma pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Inhibitor with six drugs in Phase III. The Neurofibroma pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Neurofibroma pipeline products market including Small Molecule.

Neurofibroma overview

Neurofibromas are benign (non-cancerous) tumors that grow on nerves in the body. They consist of an overgrowth of nerve tissue along with blood vessels and other types of cells and fibres. Neurofibromas can grow on nerves in the skin (cutaneous neurofibroma), under the skin (subcutaneous neurofibroma), or deeper in the body, including in the abdomen, chest, and spine.

For a complete picture of Neurofibroma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.